olication No. 09/720,278

Paper Dated: September 24, 2004

In Reply to USPTO Correspondence of August 24, 2004

Attorney Docket No. 702-002214

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

09/720,278

Applicant

Pieter Jacob Swart et al.

Filed

May 24, 2001

Title

"Pharmaceutical Preparations for Use in Combatting or Preventing

Surface Infections Caused by Microorganisms"

Group Art Unit

1654

Examiner

Roy Teller

ELECTION WITH TRAVERSE

Commissioner of Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Election is in response to the Office Action dated August 24, 2004.

In response to the election of species requirements, the following elections are made with traverse. In claims 3 and 12, Applicant is asked to elect a species, and in claims 9 and 12, Applicant is asked to elect a second species. The species elected with traverse are, for claims 3 and 12, bovine lactoferrin, and for claims 9 and 12, azole compounds (which embrace fluconazol).

> I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 24, 2004.

> > Kimberly N. Welday

(Typed Name of Person Mailing Paper).

24/2004

{W0144278.1}

Application No. 09/720,278

Paper Dated: September 23, 2004

In Reply to USPTO Correspondence of August 24, 2004

Attorney Docket No. 702-002214

The Examiner is respectfully requested to reconsider and to withdraw the species election requirement, even though Applicant understands that upon the allowability of a generic claim, Applicant will be entitled to examination of a reasonable additional number of species.

The reason why each species election requirement should be withdrawn is that the groups from which species' election has been requested are closely knit, homogeneous groups that can be readily searched and examined simultaneously. For example, in claims 3 and 12 all the purported species center around lactoferrin and its derivatives or similar polypeptides. In claims 9 and 12 the overlap among the purported species is profound, in that fluconazol is both a polyene and an azole compound, and 5-fluorocytosine and amphotericin(e) B are each listed twice. These tightly knit, cohesive groups would not create a searching or examination burden on the Examiner because they do not represent lists of distinctive chemical species that would be variously classified in different patent classifications.

At a minimum, the Examiner is requested to alter the articulation of species for the purposes of claims 3 and 12 to acknowledge that "lactoferrin" is an electable species. As the Examiner will appreciate from claim 4 in which "lactoferrin" per se is recited, "lactoferrin" itself is an important species of the invention and is the species which--if it is allowed to do so-Applicant would prefer to elect for claims 3 and 12. The lactoferrin subgenus in claim 3, for example, is already represented by the recited human lactoferrin, bovine lactoferrin, polycationic peptides occurring in these proteins, hydrolysates of lactoferrin, cation rich peptides originating from lactoferrin, and polypeptides having an amino acid sequence selected from SEQ IDs NO 1-28. The searching and consideration of these highly related peptides will be de facto proceed in consonance and the Examiner need not fear any undue search or examination burden by allowing election of the "lactoferrin" subgenus as a species in this case.

2

Application No. 09/720,278 Paper Dated: September 23, 2004

In Reply to USPTO Correspondence of August 24, 2004

Attorney Docket No. 702-002214

Examination and allowance of pending claims 1-15 and 22 is respectfully

requested.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON

ORKIN & HANSON P.C,

Barbara E. Johnson Registration No. 31,198

Attorney for Applicants 700 Koppers Building

436 Seventh Avenue

Pittsburgh, PA 15219-1818

Telephone: (412) 471-8815 Facsimile: (412) 471-4094

E-mail: webblaw@webblaw.com

SEP 2 7 2004 Storney's Docket No. 702-002214

T	TRANSMITTAL LET	TTER		
Commissioner for Patents				
P.O. Box 1450				
Alexandria,VA 22313-1450				
Serial No.: 09/720,278		Filing Date	May 24, 2001	
Examiner: Roy Teller		Group Art Unit: 1654		
Invention: Pharmaceutical Preparat	tions for Use in Comb			fections Caused
by Microorganisms				
A verified statement t X No additional fee is re	s/has been asserted for to establish small entit	this application uy status under 37		
After Previo	dent Claim/s	Small Entity Rate x \$ 9.00 x \$ 43.00 + \$145.00 FAL ADDITION	x \$ 86.00 + \$290.00	Charge \$ 0.00 \$ 0.00 \$ 0.00 \$ 0.00
A check in the amour Time. X The Commissioner is with this communicat to Deposit Account N X Any additional filing	is enclosed in the of \$	charge payment on the No. 23-0650. The charge payment on the copie of	month Petition f of the following Please refund a	fees associated for the same of the same o
September 24, 2004 Date	Attorney for 700 Kopper	n No. 31,198 or Applicants s Building		
ertify that this correspondence is being deposited with I States Postal Service as first class mail in an envelope to Commissioner for Patents, P.O. Box 1450, a, VA 22313-1450 on September 24, 2004.	Telephone:	h Avenue PA 15219-1818 (412) 471-8815 (412) 471-4094		

E-mail: webblaw@webblaw.com

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450 on September 24, 2004.

Kimberly N. Welday

(Typed Name of Person Mailing Paper)

Date